CORRECTION - OraQuick® HIV Self-Test Now Approved for Use in Adolescents

Core Insights - OraSure Technologies, Inc. has received FDA approval for a labeling change to the OraQuick® HIV Self-Test, expanding its use to adolescents aged 14 and older, previously limited to those 17 and older [1] - The change aims to increase access to HIV testing for young people, addressing a significant gap as 19% of new HIV diagnoses in the U.S. are among individuals aged 13 to 24, with only 6% of high school students having ever been tested [2][3] Company Overview - OraSure Technologies is a leader in point-of-need and home diagnostic tests, focusing on improving access to healthcare through innovative testing solutions [1][4] - The company has been committed to providing consumers with critical information and connections to care since the launch of the OraQuick® HIV Self-Test in 2012, which includes educational materials and care linkage information [3][4] Industry Context - Increasing access to HIV testing options is crucial for ending the HIV epidemic, particularly for adolescents who test positive, emphasizing the need for early connection to care [3] - The approval of the OraQuick® HIV Self-Test for younger populations is a strategic move to combat the stigma surrounding HIV testing and improve awareness among adolescents [3]